These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20815094)

  • 1. Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
    Creaney J; Musk AW; Robinson BW
    J Thorac Oncol; 2010 Sep; 5(9):1461-6. PubMed ID: 20815094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
    Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
    Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
    Hollevoet K; Reitsma JB; Creaney J; Grigoriu BD; Robinson BW; Scherpereel A; Cristaudo A; Pass HI; Nackaerts K; Rodríguez Portal JA; Schneider J; Muley T; Di Serio F; Baas P; Tomasetti M; Rai AJ; van Meerbeeck JP
    J Clin Oncol; 2012 May; 30(13):1541-9. PubMed ID: 22412141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
    Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
    Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
    Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
    Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
    Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
    Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
    Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.